Brief: Lidds AB Says Nanozolid Formulated Docetaxel Is Safe And Tolerable Showing Signs Of Clinical Efficacy
04/10/2021 18:35
Oct 4 (Reuters) - Lidds AB LIDDS.ST :
* NANOZOLID FORMULATED DOCETAXEL IS SAFE AND TOLERABLE
SHOWING
SIGNS OF CLINICAL EFFICACY
* NO FURTHER PATIENTS WILL BE ENROLLED IN ITS DOSE
ESCALATING
PHASE I STUDY
* DATA COLLECTED IN TRIAL DEMONSTRATES SAFETY AND
TOLERABILITY
* PLAN TO COMMUNICATE TOPLINE RESULTS FROM STUDY IN Q4 2021
Source text for Eikon: ID:nGNEsPKNS
Further company coverage: LIDDS.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest